GSK To Buy Nuvalent For $10.6B at 40% Premium
NUVL•GSK will acquire Nuvalent for $10.6 billion, paying $124 per share in cash—a 40% premium over its closing price. The deal adds two late-stage NSCLC therapies with FDA decisions expected this year, projected to contribute to GSK’s revenue growth from 2027.
1. Deal Terms
GSK agreed to acquire Nuvalent in an all-cash transaction valuing the biotech firm at $10.6 billion. The $124 per share offer represents a 40% premium over Nuvalent’s last closing price, reflecting GSK’s commitment to secure the company’s oncology assets.
2. Strategic Rationale
The purchase marks GSK’s largest deal in eight years as it accelerates its return to oncology under CEO Luke Miels. Nuvalent’s precision-targeted therapies for non-small-cell lung cancer bolster GSK’s pipeline and signal a renewed focus on high-growth therapeutic areas.
3. Pipeline and Approvals
Nuvalent brings two late-stage NSCLC candidates that target specific mutations in non-smokers, both pending FDA decisions later this year. If approved, these drugs could become blockbusters and are expected to drive revenue growth for GSK starting in 2027.
